The precision interventions for severe and/or exacerbation-prone asthma (PrecISE) adaptive platform trial: statistical considerations

Anastasia Ivanova, Elliot Israel, Lisa M. LaVange, Michael C. Peters, Loren C. Denlinger, Wendy C. Moore, Leonard B. Bacharier, M. Alison Marquis, Nathan M. Gotman, Michael R. Kosorok, Chalmer Tomlinson, David T. Mauger, Steve N. Georas, Rosalind J. Wright, Patricia Noel, Gary L. Rosner, Praveen Akuthota, David D Billheimer, Eugene R. Bleecker, Juan Carlos CardetMario Castro, Emily A. DiMango, Serpil C. Erzurum, John V. Fahy, Merritt L. Fajt, Benjamin M. Gaston, Fernando Holguin, Sonia Jain, Nicholas J. Kenyon, Jerry A. Krishnan, Monica Kraft, Rajesh Kumar, Mark C. Liu, Ngoc P. Ly, James N. Moy, Wanda Phipatanakul, Kristie Ross, Lewis J. Smith, Stanley J. Szefler, W. Gerald Teague, Michael E. Wechsler, Sally E. Wenzel, Steven R. White

Research output: Contribution to journalArticlepeer-review

Abstract

The Precision Interventions for Severe and/or Exacerbation-prone Asthma (PrecISE) study is an adaptive platform trial designed to investigate novel interventions to severe asthma. The study is conducted under a master protocol and utilizes a crossover design with each participant receiving up to five interventions and at least one placebo. Treatment assignments are based on the patients’ biomarker profiles and precision health methods are incorporated into the interim and final analyses. We describe key elements of the PrecISE study including the multistage adaptive enrichment strategy, early stopping of an intervention for futility, power calculations, and the primary analysis strategy.

Original languageEnglish (US)
JournalJournal of Biopharmaceutical Statistics
DOIs
StateAccepted/In press - 2020

Keywords

  • adaptive enrichment
  • compex
  • covariate adaptive randomization
  • Master protocol
  • platform trial
  • severe asthma

ASJC Scopus subject areas

  • Statistics and Probability
  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'The precision interventions for severe and/or exacerbation-prone asthma (PrecISE) adaptive platform trial: statistical considerations'. Together they form a unique fingerprint.

Cite this